Short Interest in Iterum Therapeutics PLC (NASDAQ:ITRM) Increases By 23.7%

Iterum Therapeutics PLC (NASDAQ:ITRM) was the recipient of a large growth in short interest in the month of January. As of January 30th, there was short interest totaling 1,960,331 shares, a growth of 23.7% from the January 15th total of 1,584,707 shares. Approximately 3.8% of the company’s stock are short sold. Based on an average daily trading volume, of 365,626 shares, the days-to-cover ratio is presently 5.4 days. Based on an average daily trading volume, of 365,626 shares, the days-to-cover ratio is presently 5.4 days. Approximately 3.8% of the company’s stock are short sold.

Iterum Therapeutics Stock Performance

Shares of ITRM stock opened at $0.27 on Tuesday. The company has a market capitalization of $14.64 million, a price-to-earnings ratio of -0.37 and a beta of 2.97. Iterum Therapeutics has a one year low of $0.26 and a one year high of $1.58. The company’s 50-day moving average is $0.34 and its 200 day moving average is $0.54.

Iterum Therapeutics (NASDAQ:ITRM) last issued its earnings results on Friday, November 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.07). The business had revenue of $0.39 million for the quarter. As a group, research analysts predict that Iterum Therapeutics will post -0.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on ITRM. Wall Street Zen cut shares of Iterum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Iterum Therapeutics in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $9.00.

Institutional Investors Weigh In On Iterum Therapeutics

Several institutional investors have recently modified their holdings of ITRM. Apollon Financial LLC increased its holdings in Iterum Therapeutics by 151.8% in the 4th quarter. Apollon Financial LLC now owns 630,250 shares of the company’s stock worth $211,000 after buying an additional 380,000 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Iterum Therapeutics by 1,893.5% during the 4th quarter. Jane Street Group LLC now owns 289,410 shares of the company’s stock valued at $97,000 after acquiring an additional 274,892 shares during the last quarter. Alchemi Wealth LLC purchased a new stake in shares of Iterum Therapeutics during the 4th quarter valued at about $90,000. OneDigital Investment Advisors LLC grew its stake in shares of Iterum Therapeutics by 18.6% in the third quarter. OneDigital Investment Advisors LLC now owns 191,000 shares of the company’s stock worth $128,000 after acquiring an additional 30,000 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Iterum Therapeutics during the third quarter valued at approximately $32,000. 9.21% of the stock is owned by hedge funds and other institutional investors.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).